Huda Y. Zoghbi - 10 Aug 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: Director
Issuer ticker: REGN
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:14:48 UTC
Prior SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Huda Y. Zoghbi

Key filing fact

Huda Y. Zoghbi filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 12 Aug 2026.

Key facts

This page summarizes Huda Y. Zoghbi's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2026, 16:14.

Change

Previous filing in this sequence was filed on 23 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001681643 Primary reporting owner

Zoghbi Huda Y

Relationship: Director
Address: 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature: /s/ Huda Y. Zoghbi
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +800
Change %: +47%
Price: $376.69^*
Shares after: 2,503
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

REGN transaction

Common Stock

Sale

Transaction value
Shares: -800
Change %: -32%
Price: $800.00^*
Shares after: 1,703
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -800
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 800
Exercise price: $376.69
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Footnote F2

The stock option vested in three equal annual installments, commencing one year after the date of grant.